← Back to headlines
Bioventus Reports Growth in PNS, PRP and Improved Financials
Bioventus has highlighted growth in its Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP) segments, alongside improvements in cash flow and a reduction in debt.
8 Jun, 23:03 — 8 Jun, 23:03
Sources
Showing 1 of 1 sources
